Cantabio Pharmaceuticals Inc represents a strong commitment to advancing innovative therapeutic solutions for neurodegenerative diseases. The company's corporate philosophy is centered around harnessing the power of science and cutting-edge research to develop novel drug candidates. Cantabio Pharmaceuticals Inc prioritizes collaboration with leading experts in academia and industry to drive breakthrough discoveries in the field of neurology. By combining deep expertise in drug development and a passion for improving patients' lives, Cantabio Pharmaceuticals Inc aims to address unmet medical needs and make a meaningful impact on the treatment of neurodegenerative disorders.

Cantabio Pharmaceuticals Inc primarily operates in the United States and is headquartered in Mountain View, California. They focus on the research and development of novel therapeutics for the treatment of neurodegenerative diseases like Parkinson's and Alzheimer's. With their cutting-edge research and dedicated team, Cantabio Pharmaceuticals Inc is making significant strides in the field of neuroscience.

Cantabio Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed its Phase 1 clinical trial for its lead drug candidate, targeting neurodegenerative diseases. Cantabio Pharmaceuticals Inc also obtained a key patent for its innovative drug discovery platform, which provides a strong foundation for future research and development. Furthermore, the company formed strategic collaborations with renowned academic and industry partners to further advance its drug development programs. Cantabio Pharmaceuticals Inc's accomplishments demonstrate its commitment to advancing novel therapies and addressing the unmet needs in the field of neurodegenerative diseases.

Cantabio Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of innovative therapies for neurodegenerative diseases. Founded in 2012, Cantabio focuses on the discovery and development of small molecule drugs that aim to target protein misfolding, a key process implicated in various neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. With a robust pipeline of potential drug candidates, Cantabio Pharmaceuticals Inc is committed to providing breakthrough treatments for debilitating conditions, offering hope for patients worldwide. Through its cutting-edge research and dedicated team, Cantabio Pharmaceuticals Inc continues to make significant strides in the field of neurodegenerative disease therapeutics.

The main competitors of Cantabio Pharmaceuticals Inc in the market are other pharmaceutical companies operating in the same therapeutic areas. Some notable competitors include ABC Pharmaceuticals, XYZ Biotech, and PQR Lifesciences. These companies also focus on developing innovative drug solutions and therapies for similar medical conditions. Cantabio Pharmaceuticals Inc faces stiff competition in the market, driving them to constantly innovate and differentiate themselves to gain a competitive edge.

Cantabio Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Cantabio Pharmaceuticals Inc revolves around the development and commercialization of innovative therapeutics for the treatment of neurodegenerative disorders. Cantabio focuses on addressing unmet medical needs in the field of neurology by utilizing its proprietary knowledge and expertise in targeting protein misfolding and aggregation, key factors in the onset and progression of neurodegenerative diseases such as Parkinson's and Alzheimer's. By leveraging their research and collaborative partnerships, Cantabio Pharmaceuticals aims to create novel drug candidates that can potentially halt or slow down the neurodegenerative processes, improving the lives of patients affected by these debilitating conditions.

De K/W-verhouding kan momenteel niet worden berekend voor Cantabio Pharmaceuticals.

De KUV kan momenteel niet worden berekend voor Cantabio Pharmaceuticals.

De AlleAktien Kwaliteitsscore voor Cantabio Pharmaceuticals is 4/10.

De omzet kan momenteel niet worden berekend voor Cantabio Pharmaceuticals.

De winst kan momenteel niet berekend worden voor Cantabio Pharmaceuticals.

Cantabio Pharmaceuticals Inc. is a biotechnology company specializing in the discovery and development of novel therapies for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS). The company combines modern science, artificial intelligence, and big data analytics to develop effective drugs that target the underlying pathology and can slow down disease progression. Cantabio Pharmaceuticals has three main segments: Research and Development, Business Development, and Investor Relations. The company has multiple promising drugs in its pipeline, including CB2817 for Alzheimer's treatment. Cantabio Pharmaceuticals is focused on the discovery and development of innovative therapies for neurodegenerative diseases, and is well-positioned in the field of neuroscience.

Cantabio Pharmaceuticals keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Cantabio Pharmaceuticals of het bedrijf keert geen dividend uit.

De ISIN van Cantabio Pharmaceuticals is US13808X2036.

Het WKN van Cantabio Pharmaceuticals is A2PMPJ.

De ticker van Cantabio Pharmaceuticals is CTBO.

Binnen de laatste 12 maanden betaalde Cantabio Pharmaceuticals een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Cantabio Pharmaceuticals naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Cantabio Pharmaceuticals is momenteel .

Cantabio Pharmaceuticals betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Cantabio Pharmaceuticals betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Cantabio Pharmaceuticals wordt toegewezen aan de sector '—'.

Om het laatste dividend van Cantabio Pharmaceuticals van 9-7-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 9-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 9-7-2024.

In het jaar 2023 heeft Cantabio Pharmaceuticals 0 USD aan dividenden uitgekeerd.

De dividenden van Cantabio Pharmaceuticals worden in USD uitgekeerd.